Stellar et al PNAS vol. 92, p 11970-11974.* |
Crooke et al “Antisense Research & Applications” p 1-50, 1998.* |
Branch TIBS Fe. 23, 1998 p 45-50.* |
Agrawal, S. “Antisense oligonucleotides: towards clinical trials” Tibtech, Oct. 1996, vol. 14, pp. 376-387.* |
Trojan et al., PNAS, vol. 91, p 6088-6092, Jun. 1994.* |
Toretsky and Helman, “Involvement of IGF-II in human cancer,” Journal of Endocrinology, 149: 367-372, 1996. |
Werner and LeRoith, “The role of the insulin-like growth factor system in human cancer,” Advances in Cancer Research, 68: 183-223, 1996. |
Rogler, et al., “Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice,” The Journal of Biological Chemistry, 269(19): 13779-13784, 1994. |
Bates, et al., “Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II),” British Journal of Cancer, 72: 1189-1193, 1995. |
Cullen et al., “Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes asociated with malignant progression,” Molecular Endocrinology, 6(1): 91-100, 1992. |
Werner, et al., D. “Molecular and cellular aspects of insulin-like growth factor action,” Vitamins and Hormones, 48: 1-58, 1994. |
Curcio, et al., “Oligonucleotides as modulators of cancer gene expression,” Pharmacol. Ther. 74(3): 317-332, 1997. |
Narayanan and Akhtar, “Antisense therapy,” Current Opinion in Oncology, 8: 509-515, 1996. |
Ho and Parkinson, “Antisense oligonucleotides as therapeutics for malignant diseases,” Seminars in Oncology, 24(2): 187-202, 1997. |
Crooke and Bennett, “Progress in antisense oligonucleotide therapeutics,” Annu Rev Pharmacol Toxicol., 36: 107-129, 1996. |
Christofori, et al. “A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis,” Nature, 369: 414-417, 1994. |
El-Badry, et al., “Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors,” Cell Growth & Differentiation, 1: 325-331, 1990. |
Kim, et al., “Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma,” Cancer Research, 58: 348-351, 1998. |
Volpert et al., “The insulin-like growth factor II/mannose 6-phosphate receptor is required for proliferin-induced angiogenesis,” Endocrinology. 137(9), 3871-3876, 1996. |
Lin, et al., “Antisense oligodeoxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II,” J Biochem (Tokyo). 122: 717-722, 1997. |
Steller, et al., “Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells,” Cancer Res. 56(8): 1761-1765, 1996. |
Steller, et al., “Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells,” Proc Natl Acad Sci USA, 92(26): 11970-11974, 1995. |
Cole, et al., “Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line,” Science 258:1650-1654, 1992. |
Nielsen et al., “Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide,” Science 254:1497-1500, 1991. |
Good and Nielsen, “Inhibition of translation and bacterial growth by peptide nucleic acid targeted to ribosomal RNA,” Proc Natl Acad Sci USA, 95: 2073-2076, 1998. |
Sullivan, “Development of ribozymes for gene therapy,” The Journal of Investigative Dermatology, 103(5): 85S-89S, 1994. |
Kimura et al., “Inhiition of IGF-II-stimulated growth of prostate cancer cells by IGF-I receptor specific monoclonal antibody and antisense oligonucleotide of IGF-II messenger RNA,” Journal of Urology, 151 (5 Suppl): 367A, Abstract 560, 1994. |
Trojan et al., “Gene therapy of murine teratocarcinoma: separate functions for insulin-like growth factors I and II in immunogenicity and diiffernetiation,” Proc Natl Acad Sci USA, 91: 6088-6092, 1994. |
Ham et al., “Inhibition of hepatocellular carcinoma cell growth by the extract of symphytum offincinale L. and the possible mechanisms for this inhibition,” J. Food Sci. Nutr. 2(3): 236-240, 1997. |
Baccarini et al., “Detection of anti-sense transcripts of the insulin-like growth factor-2 gene Wilms' tumor,” American Journal of Pathology, 143(6): 1535-1542, 1993. |
Brunner et al., “Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II),” Eur. J. Cancer, 29A(4): 562-569, 1993. |
Lafarge-Frayssinet et al., “Antisense insulin-like growth factor I transferred into a rat hepatoma cell line inhibits tumorigenesis by modulating major histocompatability complex I cell surface expression,” Cancer Gene Therapy, 4(5): 276-285, 1997. |